Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 4, Study to Evaluate the Safety and Efficacy of Lesinurad 200 mg in Combination With a Xanthine Oxidase Inhibitor (XOI), Compared With an XOI Alone, in Subjects With Gout and Estimated Creatinine Clearance (eCrCl) 30 to <60 mL/Min Who Have Not Achieved Target Serum Uric Acid Levels (sUA) on an XOI Alone

Trial Profile

A Phase 4, Study to Evaluate the Safety and Efficacy of Lesinurad 200 mg in Combination With a Xanthine Oxidase Inhibitor (XOI), Compared With an XOI Alone, in Subjects With Gout and Estimated Creatinine Clearance (eCrCl) 30 to <60 mL/Min Who Have Not Achieved Target Serum Uric Acid Levels (sUA) on an XOI Alone

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 29 Jan 2019

At a glance

  • Drugs Lesinurad (Primary)
  • Indications Gout
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Ironwood Pharmaceuticals
  • Most Recent Events

    • 17 Jan 2019 Planned End Date changed from 1 Dec 2022 to 31 Jan 2019.
    • 17 Jan 2019 Planned primary completion date changed from 1 Dec 2022 to 31 Jan 2019.
    • 17 Jan 2019 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top